An NIH-funded team at Cornell University has developed a compound delivered into the nose that blocked a protein used by SARS-CoV-2 to get into cells and prevented severe infection in mice. Antiviral drugs that target host cells may work against many existing and future variants of the virus that causes COVID-19. Source: NIH Research Matters